Crossmark

Comparison of long term efficacy and cost-effectiveness of omalizumab in 150 mg and 300 mg doses in patients with chronic spontaneous urticaria

Crossref DOI link: https://doi.org/10.1016/j.abd.2024.02.006

Published Print: 2025-01

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Kalkan, Fikriye https://orcid.org/0000-0002-7199-436X
Yeşillik, Sait https://orcid.org/0000-0003-1160-1381
Demirel, Fevzi https://orcid.org/0000-0002-9711-6821
Sönmez, Ezgi https://orcid.org/0009-0000-4684-0003
Balaban, Yasemin https://orcid.org/0000-0002-5654-1397
İnan, Mustafa İlker https://orcid.org/0000-0002-7984-450X
Kartal, Özgür https://orcid.org/0000-0002-6666-581X
License Information

Text and Data Mining valid from 2025-01-01

Text and Data Mining valid from 2025-01-01

Version of Record valid from 2024-10-04
More Information

This article is maintained by: Elsevier

Article Title: Comparison of long term efficacy and cost-effectiveness of omalizumab in 150 mg and 300 mg doses in patients with chronic spontaneous urticaria

Journal Title: Anais Brasileiros de Dermatologia

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.abd.2024.02.006

Content Type: article

Copyright: © 2024 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U.